Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2010, Article ID 546826, 14 pages
http://dx.doi.org/10.1155/2010/546826
Review Article

Inflammatory Mediators and Angiogenic Factors in Choroidal Neovascularization: Pathogenetic Interactions and Therapeutic Implications

1Department of Ophthalmology, University of Ferrara, Corso Giovecca 203, 44121 Ferrara, Italy
2St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK
3Department of Health Sciences, University of Molise, Campobasso, Italy
4Department of Ophthalmology, University of Brescia, Brescia, Italy
5Center for Retinitis Pigmentosa of Veneto Region, ULSS 15 Alta Padovana, Camposampiero Hospital, Camposampiero, Italy

Received 11 March 2010; Accepted 2 July 2010

Academic Editor: F. D'Acquisto

Copyright © 2010 Claudio Campa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. R. Green and D. J. Wilson, “Choroidal neovascularization,” Ophthalmology, vol. 93, no. 9, pp. 1169–1176, 1986. View at Google Scholar · View at Scopus
  2. R. Klein, T. Peto, A. Bird, and M. R. Vannewkirk, “The epidemiology of age-related macular degeneration,” American Journal of Ophthalmology, vol. 137, no. 3, pp. 486–495, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. N. M. Bressler, “Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report 1,” Archives of Ophthalmology, vol. 117, no. 10, pp. 1329–1345, 1999. View at Google Scholar · View at Scopus
  4. J. Arnold, I. Barbezetto, R. Birngruber et al., “Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2,” American Journal of Ophthalmology, vol. 131, no. 5, pp. 541–560, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. N. M. Bressler, “Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update,” Retina, vol. 25, no. 2, pp. 119–134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. U. Chakravarthy, G. Soubrane, F. Bandello et al., “Evolving European guidance on the medical management of neovascular age related macular degeneration,” British Journal of Ophthalmology, vol. 90, no. 9, pp. 1188–1196, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. D. M. Gass, Stereoscopic Atlas of Macular Diseases: Diagrams and Treatment, vol. 1, Mosby, St. Louis, Mo, USA, 1997.
  8. H. E. Grossniklaus and W. R. Green, “Choroidal neovascularization,” American Journal of Ophthalmology, vol. 137, no. 3, pp. 496–503, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. C. Killingsworth, “Angiogenesis in early choroidal neovascularization secondary to age-related macular degeneration,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 233, no. 6, pp. 313–323, 1995. View at Google Scholar · View at Scopus
  10. H. E. Grossniklaus and W. R. Green, “Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization,” Archives of Ophthalmology, vol. 116, no. 6, pp. 745–749, 1998. View at Google Scholar
  11. H. E. Grossniklaus, J. X. Ling, T. M. Wallace et al., “Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization,” Molecular Vision, vol. 21, no. 8, pp. 119–126, 2002. View at Google Scholar · View at Scopus
  12. C. Tsutsumi-Miyahara, K. H. Sonoda, and K. H. Sonoda, “The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation,” British Journal of Ophthalmology, vol. 88, no. 9, pp. 1217–1222, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. D. G. Espinosa-Heidmann, M. A. Reinoso, Y. Pina, K. G. Csaky, A. Caicedo, and S. W. Cousins, “Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization,” Experimental Eye Research, vol. 80, no. 3, pp. 369–378, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. C. M. Sheridan, D. Rice, P. S. Hiscott, D. Wong, and D. L. Kent, “The presence of AC133-positive cells suggests a possible role of endothelial progenitor cells in the formation of choroidal neovascularization,” Investigative Ophthalmology & Visual Science, vol. 47, no. 4, pp. 1642–1645, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. F. Spaide, “Rationale for combination therapies for choroidal neovascularization,” American Journal of Ophthalmology, vol. 141, no. 1, pp. 149–156, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. P. F. Lopez, B. D. Sippy, H. M. Lambert, A. B. Thach, and D. R. Hinton, “Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes,” Investigative Ophthalmology & Visual Science, vol. 37, no. 5, pp. 855–868, 1996. View at Google Scholar · View at Scopus
  17. A. Kvanta, P. V. Algvere, L. Berglin, and S. Seregard, “Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor,” Investigative Ophthalmology & Visual Science, vol. 37, no. 9, pp. 1929–1934, 1996. View at Google Scholar · View at Scopus
  18. T. Ishibashi, Y. Hata, H. Yoshikawa, K. Nakagawa, K. Sueishi, and H. Inomata, “Expression of vascular endothelial growth factor in experimental choroidal neovascularization,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 235, no. 3, pp. 159–167, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Wada, N. Ogata, T. Otsuji, and M. Uyama, “Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization,” Current Eye Research, vol. 18, no. 3, pp. 203–213, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Otani, H. Takagi, H. Oh, S. Koyama, Y. Ogura, M. Matumura, and Y. Honda, “Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes,” Microvascular Research, vol. 64, no. 1, pp. 162–169, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. H. G. T. Blaauwgeers, G. M. Holtkamp, and G. M. Holtkamp, “Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation,” American Journal of Pathology, vol. 155, no. 2, pp. 421–428, 1999. View at Google Scholar · View at Scopus
  22. N. Ferrara, H. P. Gerber, and J. Le Couter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. K. Alitalo, T. Tammela, and T. V. Petrova, “Lymphangiogenesis in development and human disease,” Nature, vol. 438, no. 7070, pp. 946–953, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. N. Ferrara, “Vascular endothelial growth factor: basic science and clinical progress,” Endocrine Reviews, vol. 25, no. 4, pp. 581–611, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. K. A. Houck, D. W. Leung, A. M. Rowland, J. Winer, and N. Ferrara, “Dual regulation of vascular endothelial growth factor,” The Journal of Biological Chemistry, vol. 267, no. 36, pp. 26031–26037, 1992. View at Google Scholar · View at Scopus
  26. B. A. Keyt, L. T. Berleau, H. V. Nguyen, H. Chen, H. Heinsohn, R. Vandlen, and N. Ferrara, “The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency,” The Journal of Biological Chemistry, vol. 271, no. 13, pp. 7788–7795, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Lee, S. M. Jilani, G. V. Nikolova, D. Carpizo, and M. Luisa Iruela-Arispe, “Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors,” Journal of Cell Biology, vol. 169, no. 4, pp. 681–691, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. C. de Vries, J. A. Escobedo, H. Ueno, K. Houck, N. Ferrara, and L. T. Williams, “The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor,” Science, vol. 255, no. 5047, pp. 989–991, 1992. View at Google Scholar · View at Scopus
  29. H. E. Grossniklaus, J. A. Martinez, and J. A. Martinez, “Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration,” American Journal of Ophthalmology, vol. 114, no. 4, pp. 464–472, 1992. View at Google Scholar · View at Scopus
  30. R. N. Frank, R. H. Amin, D. Eliott, J. E. Puklin, and G. W. Abrams, “Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes,” American Journal of Ophthalmology, vol. 122, no. 3, pp. 393–403, 1996. View at Google Scholar · View at Scopus
  31. R. Hera, M. Keramidas, M. Peoc'h, M. Mouillon, J. P. Romanet, and J. J. Feige, “Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration,” American Journal of Ophthalmology, vol. 139, no. 4, pp. 589–596, 2005. View at Google Scholar · View at Scopus
  32. L. P. Aiello, R. L. Avery, P. G. Arrigg et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” The New England Journal of Medicine, vol. 331, no. 22, pp. 1480–1487, 1994. View at Publisher · View at Google Scholar · View at Scopus
  33. J. A. Wells, R. Murthy, R. Chibber, A. Nunn, P. A. Molinatti, E. M. Kohner, and Z. J. Gregor, “Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation,” British Journal of Ophthalmology, vol. 80, no. 4, pp. 363–366, 1996. View at Google Scholar · View at Scopus
  34. K. Spilsbury, K. L. Garrett, W. Y. Shen, I. J. Constable, and P. E. Rakoczy, “Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization,” American Journal of Pathology, vol. 157, no. 1, pp. 135–144, 2000. View at Google Scholar · View at Scopus
  35. K. G. Csaky, J. Z. Baffi, G. A. Byrnes, J. D. Wolfe, S. C. Hilmer, J. Flippin, and S. W. Cousins, “Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor,” Experimental Eye Research, vol. 78, no. 6, pp. 1107–1116, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. M. G. Krzystolik, M. A. Afshari, and M. A. Afshari, “Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment,” Archives of Ophthalmology, vol. 120, no. 3, pp. 338–346, 2002. View at Google Scholar · View at Scopus
  37. Y. Saishin, Y. Saishin, and Y. Saishin, “VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier,” Journal of Cellular Physiology, vol. 195, no. 2, pp. 241–248, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. M. J. Tolentino, J. W. Miller, E. S. Gragoudas, K. Chatzistefanou, N. Ferrara, and A. P. Adamis, “Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate,” Archives of Ophthalmology, vol. 114, no. 8, pp. 964–970, 1996. View at Google Scholar · View at Scopus
  39. C. M. Sheridan, S. Pate, P. Hiscott, D. Wong, D. M. Pattwell, and D. Kent, “Expression of hypoxia-inducible factor-1α and -2α in human choroidal neovascular membranes,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 247, no. 10, pp. 1361–1367, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. T. Asahara, T. Takahashi, and T. Takahashi, “VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells,” The EMBO Journal, vol. 18, no. 14, pp. 3964–3972, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. E. Guerin, C. M. Sheridan, D. Assheton, D. Kent, D. Wong, M. Grant, and P. Hiscott, “SDF1-alpha is associated with VEGFR-2 in human choroidal neovascularisation,” Microvascular Research, vol. 75, no. 3, pp. 302–307, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. W. J. Lamoreaux, M. E. C. Fitzgerald, A. Reiner, K. A. Hasty, and S. T. Charles, “Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro,” Microvascular Research, vol. 55, no. 1, pp. 29–42, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. M. Clauss, M. Gerlach, and M. Gerlach, “Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration,” Journal of Experimental Medicine, vol. 172, no. 6, pp. 1535–1545, 1990. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Barleon, S. Sozzani, D. Zhou, H. A. Weich, A. Mantovani, and D. Marmé, “Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1,” Blood, vol. 87, no. 8, pp. 3336–3343, 1996. View at Google Scholar · View at Scopus
  45. D. G. Espinosa-Heidmann, I. J. Suner, E. P. Hernandez, D. Monroy, K. G. Csaky, and S. W. Cousins, “Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization,” Investigative Ophthalmology & Visual Science, vol. 44, no. 8, pp. 3586–3592, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Noda, H. She, T. Nakazawa, A. Hafezi-Moghadam et al., “Vascular adhesion protein-1 blockade suppresses choroidal neovascularization,” The FASEB Journal, vol. 22, no. 8, pp. 2928–2935, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. Z. M. Bian, S. G. Elner, R. M. Strieter, S. L. Kunkel, N. W. Lukacs, and V. M. Elner, “IL-4 potentiates IL-1β- and TNF-α-stimulated IL-8 and MCP-1 protein production in human retinal pigment epithelial cells,” Current Eye Research, vol. 18, no. 5, pp. 349–357, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. S. A. Mousa, W. Lorelli, and P. A. Campochiaro, “Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells,” Journal of Cellular Biochemistry, vol. 74, no. 1, pp. 135–143, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Izumi-Nagai, N. Nagai, and N. Nagai, “Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization,” American Journal of Pathology, vol. 170, no. 6, pp. 2149–2158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. M. I. Roh, H. S. Kim, J. H. Song, J. B. Lim, H. J. Koh, and O. W. Kwon, “Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed cnv associated with amd after bevacizumab treatment,” Retina, vol. 29, no. 4, pp. 523–529, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. R. S. Apte, J. Richter, J. Herndon, and T. A. Ferguson, “Macrophages inhibit neovascularization in a murine model of age-related macular degeneration,” PLoS Medicine, vol. 3, no. 8, article e310, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. F. C. Barouch and J. W. Miller, “Potential future targets for treating ocular neovascularization,” Ophthalmology Clinics of North America, vol. 19, no. 3, pp. 401–409, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. A. C. Lambooij, K. H. M. van Wely, D. J. Lindenbergh-Kortleve, R. W. A. M. Kuijpers, M. Kliffen, and C. M. Mooy, “Insulin-like growth factor-I and its receptor in neovascular age-related macular degeneration,” Investigative Ophthalmology & Visual Science, vol. 44, no. 5, pp. 2192–2198, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. M. A. Economou, J. Wu, and J. Wu, “Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor,” Investigative Ophthalmology & Visual Science, vol. 49, no. 6, pp. 2620–2626, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. S. Moncada, R. M. J. Palmer, and E. A. Higgs, “Nitric oxide: physiology, pathophysiology, and pharmacology,” Pharmacological Reviews, vol. 43, no. 2, pp. 109–142, 1991. View at Google Scholar · View at Scopus
  56. A. Ando, A. Yang, H. Nambu, and P. A. Campochiaro, “Blockade of nitric-oxide synthase reduces choroidal neovascularization,” Molecular Pharmacology, vol. 62, no. 3, pp. 539–544, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. M. S. O'Reilly, L. Holmgren, and L. Holmgren, “Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma,” Cell, vol. 79, no. 2, pp. 315–328, 1994. View at Publisher · View at Google Scholar · View at Scopus
  58. C. C. Lai, W. C. Wu, and W. C. Wu, “Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin,” Investigative Ophthalmology & Visual Science, vol. 42, no. 10, pp. 2401–2407, 2001. View at Google Scholar · View at Scopus
  59. M. S. O'Reilly, T. Boehm, and T. Boehm, “Endostatin: an endogenous inhibitor of angiogenesis and tumor growth,” Cell, vol. 88, no. 2, pp. 277–285, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Mori, A. Ando, and A. Ando, “Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin,” American Journal of Pathology, vol. 159, no. 1, pp. 313–320, 2001. View at Google Scholar · View at Scopus
  61. D. W. Dawson, O. V. Volpert, P. Gillis, S. E. Crawford, H. J. Xu, W. Benedict, and N. P. Bouck, “Pigment epithelium-derived factor: a potent inhibitor of angiogenesis,” Science, vol. 285, no. 5425, pp. 245–248, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Saishin, R. L. Silva, and R. L. Silva, “Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye,” Human Gene Therapy, vol. 16, no. 4, pp. 473–478, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. P. Gehlbach, A. M. Demetriades, and A. M. Demetriades, “Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization,” Gene Therapy, vol. 10, no. 8, pp. 637–646, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. A. Takeda, J. Z. Baffi, and J. Z. Baffi, “CCR3 is a target for age-related macular degeneration diagnosis and therapy,” Nature, vol. 460, no. 7252, pp. 225–230, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. M. A. De La Paz, Y. Itoh, C. A. Toth, and H. Nagase, “Matrix metalloproteinases and their inhibitors in human vitreous,” Investigative Ophthalmology & Visual Science, vol. 39, no. 7, pp. 1256–1260, 1998. View at Google Scholar · View at Scopus
  66. B. Steen, S. Sejersen, L. Berglin, S. Seregard, and A. Kvanta, “Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes,” Investigative Ophthalmology & Visual Science, vol. 39, no. 11, pp. 2194–2200, 1998. View at Google Scholar · View at Scopus
  67. V. Lambert, C. Munaut, M. Jost, A. Noël, Z. Werb, J. M. Foidart, and J. M. Rakic, “Matrix metalloproteinase-9 contributes to choroidal neovascularization,” American Journal of Pathology, vol. 161, no. 4, pp. 1247–1253, 2002. View at Google Scholar · View at Scopus
  68. V. Lambert, B. Wielockx, C. Munaut et al., “MMP-2 and MMP-9 synergize in promoting choroidal neovascularization,” The FASEB Journal, vol. 17, no. 15, pp. 2290–2292, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. T. Takahashi, T. Nakamura, and T. Nakamura, “Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells,” American Journal of Ophthalmology, vol. 130, no. 6, pp. 774–781, 2000. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Otani, H. Takagi, H. Oh, S. Koyama, M. Matsumura, and Y. Honda, “Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes,” Investigative Ophthalmology & Visual Science, vol. 40, no. 9, pp. 1912–1920, 1999. View at Google Scholar · View at Scopus
  71. M. Lu and A. P. Adamis, “Molecular biology of choroidal neovascularization,” Ophthalmology Clinics of North America, vol. 19, no. 3, pp. 323–334, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. R. Amin, J. E. Puklin, and R. N. Frank, “Growth factor localization in choroidal neovascular membranes of age- related macular degeneration,” Investigative Ophthalmology & Visual Science, vol. 35, no. 8, pp. 3178–3188, 1994. View at Google Scholar · View at Scopus
  73. N. Ogata, C. Yamamoto, M. Miyashiro, H. Yamada, M. Matsushima, and M. Uyama, “Expression of transforming growth factor-β mRNA in experimental choroidal neovascularization,” Current Eye Research, vol. 16, no. 1, pp. 9–18, 1997. View at Publisher · View at Google Scholar · View at Scopus
  74. W. Hu, M. H. Criswell, S. L. Fong, C. J. Temm, G. Rajashekhar, T. L. Cornell, and M. A. Clauss, “Differences in the temporal expression of regulatory growth factors during choroidal neovascular development,” Experimental Eye Research, vol. 88, no. 1, pp. 79–91, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. P. S. Bora, J. H. Sohn, and J. H. Sohn, “Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization,” The Journal of Immunology, vol. 174, no. 1, pp. 491–497, 2005. View at Google Scholar · View at Scopus
  76. G. S. Hageman, D. H. Anderson, and D. H. Anderson, “A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 20, pp. 7227–7232, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. A. O. Edwards, R. Ritter III, K. J. Abel, A. Manning, C. Panhuysen, and L. A. Farrer, “Complement factor H polymorphism and age-related macular degeneration,” Science, vol. 308, no. 5720, pp. 421–424, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. J. L. Haines, M. A. Hauser, and M. A. Hauser, “Complement factor H variant increases the risk of age-related macular degeneration,” Science, vol. 308, no. 5720, pp. 419–421, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. R. J. Klein, C. Zeiss, and C. Zeiss, “Complement factor H polymorphism in age-related macular degeneration,” Science, vol. 308, no. 5720, pp. 385–389, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. B. J. Wegscheider, M. Weger, and M. Weger, “Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration,” Ophthalmology, vol. 114, no. 4, pp. 738–742, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. J. M. Seddon, P. J. Francis, S. George, D. W. Schultz, B. Rosner, and M. L. Klein, “Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration,” Journal of the American Medical Association, vol. 297, no. 16, pp. 1793–1800, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. M. A. Brantley Jr., S. L. Edelstein, J. M. King, R. S. Apte, S. M. Kymes, and A. Shiels, “Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration,” American Journal of Ophthalmology, vol. 144, no. 3, pp. 404–408, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. S. P. Seitsonen, P. Onkamo, G. Peng et al., “Multifactor effects and evidence of potential interaction between complement factor HY402H and LOC387715 A69S in age-related macular degeneration,” PLoS ONE, vol. 3, no. 12, article e3833, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. R. K. Shuler Jr., S. Schmidt, and S. Schmidt, “Phenotype analysis of patients with the risk variant LOC387715 (A69S) in age-related macular degeneration,” American Journal of Ophthalmology, vol. 145, no. 2, pp. 303–307, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. I. Droz, I. Mantel, A. Ambresin, M. Faouzi, D. F. Schorderet, and F. L. Munier, “Genotype-phenotype correlation of age-related macular degeneration: influence of complement factor H polymorphism,” British Journal of Ophthalmology, vol. 92, no. 4, pp. 513–517, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. N. R. Kim, J. H. Kang, O. W. Kwon, S. J. Lee, J. H. Oh, and H. S. Chin, “Association between complement factor H gene polymorphisms and neovascular age-related macular degeneration in koreans,” Investigative Ophthalmology & Visual Science, vol. 49, no. 5, pp. 2071–2076, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. I. Kaur, S. Katta, and S. Katta, “Variants in the 10q26 gene cluster (LOC387715 and HTRA1) exhibit enhanced risk of age-related macular degeneration along with CFH in Indian patients,” Investigative Ophthalmology & Visual Science, vol. 49, no. 5, pp. 1771–1776, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. M. M. Deangelis, F. Ji, and F. Ji, “Alleles in the HtrA serine peptidase 1 gene alter the risk of neovascular age-related macular degeneration,” Ophthalmology, vol. 115, no. 7, pp. 1209–1215, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. N. Leveziel, J. Zerbib, and J. Zerbib, “Genotype-phenotype correlations for exudative age-related macular degeneration associated with homozygous HTRA1 and CFH genotypes,” Investigative Ophthalmology & Visual Science, vol. 49, no. 7, pp. 3090–3094, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. N. Gotoh, R. Yamada, H. Nakanishi, M. Saito, T. Iida, F. Matsuda, and N. Yoshimura, “Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population,” Clinical and Experimental Ophthalmology, vol. 36, no. 5, pp. 437–442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Xu, N. Guan, and N. Guan, “Association of CFH, LOC387715, and HTRA1 polymorphisms with exudative age-related macular degeneration in a northern Chinese population,” Molecular Vision, vol. 14, pp. 1373–1381, 2008. View at Google Scholar · View at Scopus
  92. F. Ricci, S. Zampatti, and S. Zampatti, “Typing of ARMS2 and CFH in age-related macular degeneration: case-control study and assessment of frequency in the Italian population,” Archives of Ophthalmology, vol. 127, no. 10, pp. 1368–1372, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. P. J. Francis, H. Zhang, A. DeWan, J. Hoh, and M. L. Klein, “Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population,” Molecular Vision, vol. 14, pp. 1395–1400, 2008. View at Google Scholar · View at Scopus
  94. I. K. Kim, F. Ji, and F. Ji, “Comprehensive analysis of CRP, CFH Y402H and environmental risk factors on risk of neovascular age-related macular degeneration,” Molecular Vision, vol. 14, pp. 1487–1495, 2008. View at Google Scholar · View at Scopus
  95. R. Klein, M. D. Knudtson, and M. D. Knudtson, “Inflammation, complement factor H, and age-related macular degeneration: the multi-ethnic study of atherosclerosis,” Ophthalmology, vol. 115, no. 10, pp. 1742–1749, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. D. I. Marioli, N. Pharmakakis, A. Deli, I. Havvas, and I. K. Zarkadis, “Complement factor H and LOC 387715 gene polymorphisms in a Greek population with age-related macular degeneration,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 247, no. 11, pp. 1547–1553, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. H. Jiang, Y. Qu, and Y. Qu, “Analyses of single nucleotide polymorphisms and haplotype linkage of LOC387715 and the HTRA1 gene in exudative age-related macular degeneration in a Chinese cohort,” Retina, vol. 29, no. 7, pp. 974–979, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. R. Reynolds, M. E. Hartnett, J. P. Atkinson, P. C. Giclas, B. Rosner, and J. M. Seddon, “Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes,” Investigative Ophthalmology & Visual Science, vol. 50, no. 12, pp. 5818–5827, 2009. View at Google Scholar
  99. M. Lederman, A. Weiss, and I. Chowers, “Association of neovascular age-related macular degeneration with specific gene expression patterns in peripheral white blood cells,” Investigative Ophthalmology & Visual Science, vol. 51, no. 1, pp. 53–58, 2010. View at Google Scholar
  100. I. Kaur, S. Katta, R. K. Reddy, R. Narayanan, A. Mathai, A. B. Majji, and S. Chakrabarti, “The involvement of complement factor B and complement component C2 in an Indian cohort with age-related macular degeneration,” Investigative Ophthalmology & Visual Science, vol. 51, no. 1, pp. 59–63, 2010. View at Google Scholar
  101. P. J. Francis, S. C. Hamon, J. Ott, R. G. Weleber, and M. L. Klein, “Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss,” Journal of Medical Genetics, vol. 46, no. 5, pp. 300–307, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. S. R. de Córdoba and E. G. de Jorge, “Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H,” Clinical and Experimental Immunology, vol. 151, no. 1, pp. 1–13, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. G. S. Hageman, L. S. Hancox, and L. S. Hancox, “Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications,” Annals of Medicine, vol. 38, no. 8, pp. 592–604, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Machalińska, V. Dziedziejko, K. Mozolewska-Piotrowska, D. Karczewicz, B. Wiszniewska, and B. MacHaliński, “Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration,” Ophthalmic Research, vol. 42, no. 1, pp. 54–59, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. R. K. Jain, “Molecular regulation of vessel maturation,” Nature Medicine, vol. 9, no. 6, pp. 685–693, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  106. K. Gaengel, G. Genové, A. Armulik, and C. Betsholtz, “Endothelial-mural cell signaling in vascular development and angiogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 5, pp. 630–638, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. M. Thomas and H. G. Augustin, “The role of the angiopoietins in vascular morphogenesis,” Angiogenesis, vol. 12, no. 2, pp. 125–137, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  108. N. Jo, C. Mailhos, M. Ju et al., “Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization,” American Journal of Pathology, vol. 168, no. 6, pp. 2036–2053, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. D. Kent and C. Sheridan, “Choroidal neovascularization: a wound healing perspective,” Molecular Vision, vol. 9, pp. 747–755, 2003. View at Google Scholar · View at Scopus
  110. N. Ferrara, R. D. Mass, C. Campa, and R. Kim, “Targeting VEGF-A to treat cancer and age-related macular degeneration,” Annual Review of Medicine, vol. 58, pp. 491–504, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham Jr., M. Feinsod, and D. R. Guyer, “Pegaptanib for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. U. Chakravarthy, A. P. Adamis, E. T. Cunningham Jr. et al., “Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 9, pp. 1508–1521, 2006. View at Google Scholar
  113. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy, and T. Ianchulev, “Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study,” Ophthalmology, vol. 116, no. 1, pp. 57–65, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir, and M. J. Giust, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 3, pp. 363–372, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  117. Z. F. Bashshur, A. Bazarbachi, A. Schakal, Z. A. Haddad, C. P. El Haibi, and B. N. Noureddin, “Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration,” American Journal of Ophthalmology, vol. 142, no. 1, pp. 1–9, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  118. R. F. Spaide, K. Laud, and K. Laud, “Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration,” Retina, vol. 26, no. 4, pp. 383–390, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. R. Lazic and N. Gabric, “Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration,” Graefe's Archives for Clinical and Experimental Ophthalmology, vol. 245, no. 1, pp. 68–73, 2007. View at Google Scholar
  120. P. V. Algvere, B. Steén, S. Seregard, and A. Kvanta, “A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations,” Acta Ophthalmologica, vol. 86, no. 5, pp. 482–489, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  121. R. Ehrlich, D. Weinberger, E. Priel, and R. Axer-Siegel, “Outcome of bevacizumab (Avastin) injection in patients with age-related macular degeneration and low visual acuity,” Retina, vol. 28, no. 9, pp. 1302–1307, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  122. C. Costagliola, M. Romano, and M. Romano, “Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study,” Retina, vol. 29, no. 9, pp. 1227–1234, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  123. G. Landa, W. Amde, and W. Amde, “Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration,” Ophthalmologica, vol. 223, no. 6, pp. 370–375, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  124. K. E. Stepien, P. J. Rosenfeld, and P. J. Rosenfeld, “Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration,” Retina, vol. 29, no. 8, pp. 1067–1073, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  125. M. L. Subramanian, S. Ness, and S. Ness, “Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial,” American Journal of Ophthalmology, vol. 148, no. 6, pp. 875–882, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  126. D. S. Fong, P. Custis, J. Howes, and J. W. Hsu, “Intravitreal bevacizumab and ranibizumab for age-related macular degeneration. A multicenter, retrospective study,” Ophthalmology, vol. 117, no. 2, pp. 298–302, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  127. L. Wu, M. A. Martínez-Castellanos, and M. A. Martínez-Castellanos, “Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the pan-american collaborative retina study group (PACORES),” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 1, pp. 81–87, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  128. L. J. Wong, R. U. Desai, A. Jain, D. Feliciano, D. M. Moshfeghi, S. R. Sanislo, and M. S. Blumenkranz, “Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease,” Retina, vol. 28, no. 8, pp. 1151–1158, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  129. J. Raftery, A. Clegg, J. Jones, C. T. Seng, and A. Lotery, “Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness,” British Journal of Ophthalmology, vol. 91, no. 9, pp. 1244–1246, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  130. A. F. Cruess, G. Zlateva, and G. Zlateva, “Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study,” PharmacoEconomics, vol. 26, no. 1, pp. 57–73, 2008. View at Google Scholar · View at Scopus
  131. W. E. Smiddy, “Economic implications of current age-related macular degeneration treatments,” Ophthalmology, vol. 116, no. 3, pp. 481–487, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  132. A. V. Chappelow and P. K. Kaiser, “Neovascular age-related macular degeneration: potential therapies,” Drugs, vol. 68, no. 8, pp. 1029–1036, 2008. View at Publisher · View at Google Scholar · View at Scopus
  133. S. Slakter and CLEAR-IT 2 Investigators, “A phase 2, randomized, controlled dose-and interval-ranging study of intravitreal VEGF trap-eye in patients with neovascular age-related macular degeneration: optical coherence tomography (OCT) and fluorescein angiography (FA) outcomes at 1 Year,” Investigative Ophthalmology & Visual Science, vol. 50, 2009, abstract no. 1890. View at Google Scholar
  134. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (COBALT). [ClinicalTrials.gov identifier: NCT00499590], http://clinicaltrials.gov/ct2/show/ NCT00499590.
  135. D.S. Boyer and Ophthotech Anti-PDGF in AMD Study Group, “Combined inhibition of platelet derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD)—results of a phase 1 study,” Investigative Ophthalmology & Visual Science, vol. 50, 2009, abstract no. 1260. View at Google Scholar
  136. N. Jo, C. Mailhos, and C. Mailhos, “Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization,” American Journal of Pathology, vol. 168, no. 6, pp. 2036–2053, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. D. W. Siemann, D. J. Chaplin, and P. A. Walicke, “A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P),” Expert Opinion on Investigational Drugs, vol. 18, no. 2, pp. 189–197, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  138. H. Nambu, R. Nambu, M. Melia, and P. A. Campochiaro, “Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization,” Investigative Ophthalmology & Visual Science, vol. 44, no. 8, pp. 3650–3655, 2003. View at Publisher · View at Google Scholar · View at Scopus
  139. S. R. Russell, H. L. Hudson, and J. A. Jerdan, “Anecortave acetate for the treatment of exudative age-related macular degeneration—a review of clinical outcomes,” Survey of Ophthalmology, vol. 52, supplement 1, pp. S79–S90, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  140. T. Yasukawa, S. Hoffmann, W. Eichler, U. Friedrichs, Y. S. Wang, and P. Wiedemann, “Inhibition of experimental choroidal neovascularization in rats by an α(v)-integrin antagonist,” Current Eye Research, vol. 28, no. 5, pp. 359–366, 2004. View at Publisher · View at Google Scholar · View at Scopus
  141. Y. Fu, M. L. Ponce, M. Thill, P. Yuan, S. W. Nam, and K. G. Csaky, “Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761,” Investigative Ophthalmology & Visual Science, vol. 48, no. 11, pp. 5184–5190, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  142. A. Capone Jr., V. H. Gonzalez, and J. S. Heier, “A phase I open-label study of single and repeated doses of intravitreal JSM6427, a small molecule integrin 5β1 antagonist, in neovascular age-related macular degeneration (AMD),” Investigative Ophthalmology & Visual Science, vol. 50, 2009, abstract no. 1259. View at Google Scholar
  143. T. Takahashi, T. Nakamura, and T. Nakamura, “Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells,” American Journal of Ophthalmology, vol. 130, no. 6, pp. 774–781, 2000. View at Publisher · View at Google Scholar · View at Scopus
  144. M. V. Cano, E. D. Karagiannis, M. Soliman, B. Bakir, W. Zhuang, A. S. Popel, and P. L. Gehlbach, “A peptide derived from type 1 thrombospondin repeat-containing protein WISP-1 inhibits corneal and choroidal neovascularization,” Investigative Ophthalmology & Visual Science, vol. 50, no. 8, pp. 3840–3845, 2009. View at Google Scholar · View at Scopus
  145. K. Takahashi, Y. Saishin, and Y. Saishin, “Topical nepafenac inhibits ocular neovascularization,” Investigative Ophthalmology & Visual Science, vol. 44, no. 1, pp. 409–415, 2003. View at Publisher · View at Google Scholar · View at Scopus
  146. N. S. Dejneka, A. M. Kuroki, J. Fosnot, W. Tang, M. J. Tolentino, and J. Bennett, “Systemic rapamycin inhibits retinal and choroidal neovascularization in mice,” Molecular Vision, vol. 10, pp. 964–972, 2004. View at Google Scholar · View at Scopus
  147. Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration (EMERALD) [ClinicalTrials.gov identifier: NCT00766337], http://clinicaltrials.gov/ct2/show/NCT00766337.
  148. C.V. Regatieri, J.L. Dreyfuss, G.B. Melo et al., “Dual role of intravitreous infliximab in experimental choroidal neovascularization. Effect on the expression of sulfated glycosaminoglycans,” Investigative Ophthalmology & Visual Science, vol. 50, no. 11, pp. 5487–5494, 2009. View at Google Scholar
  149. J. L. Olson, R. J. Courtney, and N. Mandava, “Intravitreal infliximab and choroidal neovascularization in an animal model,” Archives of Ophthalmology, vol. 125, no. 9, pp. 1221–1224, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  150. T. Ueta, Y. Yanagi, Y. Tamaki, and T. Yamaguchi, “Cerebrovascular accidents in ranibizumab,” Ophthalmology, vol. 116, no. 2, p. 362, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  151. F. Parmeggiani, C. Costagliola, and C. Costagliola, “Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration,” Pharmacogenetics and Genomics, vol. 17, no. 12, pp. 1039–1046, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  152. F. Parmeggiani, C. Costagliola, D. Gemmati et al., “Coagulation-balance genetic predictors for efficacy of photodynamic therapy in occult choroidal neovascularization secondary to age-related macular degeneration,” Investigative Ophthalmology & Visual Science, vol. 49, no. 7, pp. 3100–3106, 2008. View at Google Scholar
  153. F. Parmeggiani, D. Gemmati, C. Costagliola, A. Sebastiani, and C. Incorvaia, “Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration,” Pharmacogenomics, vol. 10, no. 1, pp. 81–95, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  154. F. Parmeggiani, D. Gemmati, C. Costagliola, A. Sebastiani, and C. Incorvaia, “Predictive role of gene polymorphisms affecting thrombin-generation pathway in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration,” Recent Patents on DNA and Gene Sequences, vol. 3, no. 2, pp. 114–122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. F. Parmeggiani, D. Gemmati, and D. Gemmati, “Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia,” Ophthalmology, vol. 117, no. 3, pp. 517–523, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  156. S. V. Goverdhan, S. Hannan, R. B. Newsom, A. J. Luff, H. Griffiths, and A. J. Lotery, “An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment,” Eye, vol. 22, no. 6, pp. 849–854, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  157. I. Chowers, T. Meir, and T. Meir, “Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel,” Molecular Vision, vol. 14, pp. 2263–2271, 2008. View at Google Scholar · View at Scopus
  158. M. A. Brantley Jr., S. L. Edelstein, J. M. King, M. R. Plotzke, R. S. Apte, S. M. Kymes, and A. Shiels, “Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy,” Eye, vol. 23, no. 3, pp. 626–631, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  159. M. A. Brantley Jr., A. M. Fang, J. M. King, A. Tewari, S. M. Kymes, and A. Shiels, “Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab,” Ophthalmology, vol. 114, no. 12, pp. 2168–2173, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  160. A. Y. Lee, A. K. Raya, S. M. Kymes, A. Shiels, and M. A. Brantley Jr., “Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab,” British Journal of Ophthalmology, vol. 93, no. 5, pp. 610–613, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  161. X. Feng, J. Xiao, and J. Xiao, “Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration,” Ophthalmology, vol. 116, no. 10, pp. 1908–1912, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus